Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Case of sorafenib-induced thyroid storm.

Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SW.

J Clin Oncol. 2013 Jun 1;31(16):e262-4. doi: 10.1200/JCO.2012.46.7142. Epub 2013 Apr 22. No abstract available.

PMID:
23610115
2.

Sorafenib induced eruptive melanocytic lesions.

Uhlenhake EE, Watson AC, Aronson P.

Dermatol Online J. 2013 May 15;19(5):18184.

3.

Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.

Hegde U, Patel V, Kaloudis E.

Int J Urol. 2013 Jun;20(6):644-5. doi: 10.1111/iju.12011. Epub 2012 Nov 27. No abstract available.

4.

Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.

El Tal AK, Remichofsky CJ, Mehregan DA, Ganger LK.

Int J Dermatol. 2013 Dec;52(12):1538-41. doi: 10.1111/j.1365-4632.2012.05485.x. Epub 2013 May 15. No abstract available.

PMID:
23676092
5.

[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].

Takagi K, Takai M, Kawata K, Horie K, Kikuchi M, Kato T, Mizutani K, Seike K, Tsuchiya T, Yasuda M, Yokoi S, Nakano M, Ushikoshi H, Miyazaki T, Deguchi T.

Hinyokika Kiyo. 2015 Sep;61(9):347-51. Japanese.

6.

Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

Jpn J Clin Oncol. 2013 Oct;43(10):1023-9. doi: 10.1093/jjco/hyt110. Epub 2013 Aug 15.

PMID:
23956442
7.

Delayed onset perforating folliculitis associated with sorafenib.

Batalla A, Menéndez L, Blay P, Curto JR.

Australas J Dermatol. 2014 Aug;55(3):233-5. doi: 10.1111/ajd.12207. No abstract available.

PMID:
25117168
8.

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.

Sil A, Das NK.

Indian J Pharmacol. 2014 May-Jun;46(3):334-6. doi: 10.4103/0253-7613.132189.

9.

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P.

Br J Cancer. 2012 Nov 6;107(10):1665-71. doi: 10.1038/bjc.2012.385.

10.

[Side effects of sorafenib and countermeasures].

Nakayama M, Arai Y, Nishimura K.

Hinyokika Kiyo. 2012 Nov;58(11):635-7. Japanese.

11.

Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.

İlknur T, Akarsu S, Çarsanbali S, Lebe B, Fetil E.

J Drugs Dermatol. 2014 Aug;13(8):899-900. No abstract available.

PMID:
25116964
12.

Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.

Bellesoeur A, Carton E, Mir O, Groussin L, Blanchet B, Billemont B, Clerc J, Goldwasser F.

Invest New Drugs. 2014 Jun;32(3):569-72. doi: 10.1007/s10637-013-0052-7. Epub 2014 Jan 8.

PMID:
24399106
13.

Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.

Kumar S.

J Gastroenterol Hepatol. 2015 Mar;30(3):438. doi: 10.1111/jgh.12844. No abstract available.

PMID:
25707790
14.

Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.

Konca Degertekin C, Coşkun U, Baloş Törüner F, Aktürk M, Demirci U.

Endocrine. 2012 Dec;42(3):756-7. doi: 10.1007/s12020-012-9683-2. No abstract available.

PMID:
22562706
15.

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM, Ritchie AW, Eisen T, Macaulay VM, Protheroe A.

BMC Cancer. 2012 Dec 11;12:590. doi: 10.1186/1471-2407-12-590.

16.

Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.

Kashima T, Ohno Y, Tachibana M.

Int J Urol. 2012 Nov;19(11):1041-2. doi: 10.1111/j.1442-2042.2012.03099.x. Epub 2012 Jul 13. No abstract available.

17.

A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.

Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, Daido Y.

Keio J Med. 2015;64(4):62-4. doi: 10.2302/kjm.2015-0001-CR.

18.

Tyrosine kinase inhibitor induced pancreatitis.

Sevin A, Chen A, Atkinson B.

J Oncol Pharm Pract. 2013 Sep;19(3):257-60. doi: 10.1177/1078155212457968. Epub 2012 Oct 3.

PMID:
23034406
19.

Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.

Wolter P, Beuselinck B, Pans S, Schöffski P.

Acta Oncol. 2009;48(4):621-4. doi: 10.1080/02841860802609574. No abstract available.

PMID:
19107622
20.

Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.

Dasanu CA, Alexandrescu DT, Dutcher J.

South Med J. 2007 Mar;100(3):328-30. Erratum in: South Med J. 2007 May;100(5):485.

PMID:
17396743

Supplemental Content

Support Center